As GLP-1 medications become more widely used for weight loss and diabetes, neurologists are raising fresh concerns about their safety for people with certain neurodegenerative disorders. New clinical reports and expert warnings suggest these drugs — prized for rapid fat loss — could unintentionally hasten decline in patients with amyotrophic lateral sclerosis (ALS).
Dr. Jinsy Andrews, director of the ALS Center at NYU Langone, says the very effect that makes these therapies effective for many patients — pronounced weight reduction — may oppose the nutritional needs of those with neuromuscular disease. That tension has taken on greater urgency as prescriptions for GLP-1 receptor agonists have surged nationwide.
GLP-1 receptor agonists such as semaglutide are clinically proven to improve blood sugar control and promote sustained weight loss. Trials and observational studies have also linked these agents to lower risks of cardiovascular events, reduced fatty liver disease, and even benefits in addiction treatment. Those advantages, however, do not automatically transfer to people with progressive muscle-wasting conditions.
Amazon satellite internet launches in South Africa: Starlink rollout trails behind
MLB playoff picture: 11 teams all but eliminated
In ALS, losing body mass can carry direct clinical consequences. Standard practice often emphasizes maintaining or increasing weight to help preserve muscle strength and slow functional loss. According to Andrews, the drug-induced calorie deficit created by GLP-1s could therefore accelerate disease progression rather than protect patients.
A 2025 case report in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration illustrates that concern. Investigators described a 52-year-old woman with ALS who began semaglutide for type 2 diabetes. Her condition followed an expected decline until she lost roughly 25 pounds over three months after starting the medication; around the same time her functional scores worsened markedly. Clinicians stopped the drug, and the rapid deterioration subsequently leveled off.
That single case, combined with retrospective cohort analyses of ALS patients who also had diabetes, has prompted clinicians to advise caution. Andrews and others urge that treatment decisions weigh the metabolic benefits of GLP-1 therapy against the potential neurological risks for this population.
- For patients: If you have ALS or another neurodegenerative disease, discuss weight and muscle goals before starting GLP-1 therapy.
- For clinicians: Consider alternative glycemic strategies or closely monitor weight, nutritional status, and ALS functional measures when prescribing GLP-1s.
- For caregivers: Early recognition of rapid weight loss or a sudden change in function should prompt re-evaluation of medications and nutrition plans.
Regulatory labeling does not currently list neurodegenerative diseases as a specific warning for semaglutide products such as Ozempic or Wegovy, a point Andrews highlighted to show a gap between prescribing information and emerging clinical observations. That discrepancy underscores why frontline clinicians and specialists must communicate closely when treating patients with overlapping metabolic and neurological conditions.
While GLP-1 receptor agonists remain an important therapeutic tool for millions, the evolving evidence around ALS illustrates a broader lesson: medication effects that are beneficial in one context may be harmful in another. As use of these drugs continues to expand, targeted research and careful case-by-case clinical judgment will be essential to protect patients with rare or complex illnesses.
